R & D Pipeline

At Envision Sciences, we are dedicated to advancing the frontier of cancer diagnostics and prognostics.  At the heart of our mission is a commitment to pioneering breakthroughs that can significantly improve the detection, understanding, and prediction of cancer outcomes. These advancements are designed to help enable healthcare providers to deliver personalised treatment plans and improve patient care.


Envision was founded on innovative cancer biomarker technologies and strives to continue that approach to every facet of our scientific and commercial operations.

  • Envision has a comprehensive clinical development program where its assets are subjects of innovative clinical studies designed to deepen and broaden their utility claims with respect to diagnostic and prognostic applications.
  • Envision is currently prosecuting a highly innovative liquid-based cancer biomarker discovery and development program aimed at synergising with the multiple tissue biomarker initiatives currently in place.
  • Envision has established an innovative product optimisation strategy where the focus is on extending the utility and applicability of our products allowing them to be applied with wider scope, with longer shelf-life and greater inter-product relevance.
  • Envision’s commercial operations are also underpinned by innovation.  We work with like-minded innovative commercial partners to identify synergistic and mutually beneficial opportunities where aligning approaches to commercial activities and product synergies are actively pursued.